-
公开(公告)号：US09907828B2
公开(公告)日：2018-03-06
申请号：US14407265
申请日：2013-06-20
IPC分类号： A61K38/43 , A61K38/12 , A61K38/06 , A61K38/16 , A61K38/45 , A61K45/06 , A61K31/425 , A61K31/437 , C12N15/113 , A61K31/197 , A61K31/713
CPC分类号： A61K38/12 , A61K31/197 , A61K31/425 , A61K31/437 , A61K31/713 , A61K38/06 , A61K38/164 , A61K38/45 , A61K45/06 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12Y205/01018 , C12Y503/04001 , A61K2300/00
摘要： The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.
-
公开(公告)号：US20150157686A1
公开(公告)日：2015-06-11
申请号：US14407265
申请日：2013-06-20
IPC分类号： A61K38/12 , A61K31/437 , C12N15/113 , A61K45/06 , A61K31/713 , A61K31/425 , A61K31/197
CPC分类号： A61K38/12 , A61K31/197 , A61K31/425 , A61K31/437 , A61K31/713 , A61K38/06 , A61K38/164 , A61K38/45 , A61K45/06 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12Y205/01018 , C12Y503/04001 , A61K2300/00
摘要： The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.
摘要翻译： 本发明一般涉及用于治疗某些氧化应激状况的系统和方法。 一方面，本发明的组合物和方法可用于治疗具有氧化应激状况的受试者，例如具有肺纤维化的受试者。 在一些实施方案中，可以使用ERP57抑制剂（例如硫假皮霉素）和/或GSTP抑制剂（例如，TLK-199）来治疗受试者。 在本发明的某些方面也提供了用于这种疗法的试剂盒，用于促进这些疗法的方法等。
-
公开(公告)号：US20210353620A1
公开(公告)日：2021-11-18
申请号：US17320069
申请日：2021-05-13
发明人： Vikas Anathy , Nicolas Chamberlain , Amit Kumar
IPC分类号： A61K31/496 , C12N15/113 , C07K16/40 , A61K31/381 , A61K31/427 , A61K31/675 , A61K31/7068 , A61K35/16 , A61K39/42 , A61K39/395 , A61K31/4965 , A61K31/7048 , A61P31/14 , G01N33/50
摘要： Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.
-
公开(公告)号：US20240216365A1
公开(公告)日：2024-07-04
申请号：US18542451
申请日：2023-12-15
发明人： Vikas Anathy , Nicolas Chamberlain , Amit Kumar
IPC分类号： A61K31/496 , A61K31/381 , A61K31/427 , A61K31/4965 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K35/16 , A61K39/395 , A61K39/42 , A61P31/14 , C07K16/40 , C12N15/113 , G01N33/50
CPC分类号： A61K31/496 , A61K31/381 , A61K31/427 , A61K31/4965 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K35/16 , A61K39/3955 , A61K39/42 , A61P31/14 , C07K16/40 , C12N15/1137 , G01N33/5008 , C12N2310/14
摘要： Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.
-
公开(公告)号：US12011476B2
公开(公告)日：2024-06-18
申请号：US15931809
申请日：2020-05-14
IPC分类号： A61K38/12 , A61K31/197 , A61K31/425 , A61K31/437 , A61K31/713 , A61K38/06 , A61K38/16 , A61K38/45 , A61K45/06 , C12N15/113
CPC分类号： A61K38/12 , A61K31/197 , A61K31/425 , A61K31/437 , A61K31/713 , A61K38/06 , A61K38/164 , A61K38/45 , A61K45/06 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12Y205/01018 , C12Y503/04001 , A61K31/425 , A61K2300/00 , A61K31/437 , A61K2300/00
摘要： The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.
-
公开(公告)号：US11883395B2
公开(公告)日：2024-01-30
申请号：US17320069
申请日：2021-05-13
发明人： Vikas Anathy , Nicolas Chamberlain , Amit Kumar
IPC分类号： A61K31/496 , C07K16/40 , A61K31/381 , A61K31/427 , A61K31/675 , A61K31/7068 , A61K39/395 , A61K31/4965 , A61K31/7048 , C12N15/113 , A61K35/16 , A61K39/42 , A61P31/14 , G01N33/50
CPC分类号： A61K31/496 , A61K31/381 , A61K31/427 , A61K31/4965 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K35/16 , A61K39/3955 , A61K39/42 , A61P31/14 , C07K16/40 , C12N15/1137 , G01N33/5008 , C12N2310/14
摘要： Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.
-
公开(公告)号：US20200276263A1
公开(公告)日：2020-09-03
申请号：US15931809
申请日：2020-05-14
IPC分类号： A61K38/12 , A61K38/06 , A61K38/16 , A61K38/45 , A61K45/06 , A61K31/425 , A61K31/437 , C12N15/113 , A61K31/197 , A61K31/713
摘要： The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.
-
公开(公告)号：US10688150B2
公开(公告)日：2020-06-23
申请号：US15874136
申请日：2018-01-18
IPC分类号： A61K38/12 , A61K38/06 , A61K38/16 , A61K38/45 , A61K45/06 , A61K31/425 , A61K31/437 , C12N15/113 , A61K31/197 , A61K31/713
摘要： The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.
-
公开(公告)号：US20180221436A1
公开(公告)日：2018-08-09
申请号：US15874136
申请日：2018-01-18
IPC分类号： A61K38/12 , A61K31/713 , A61K31/197 , A61K38/06 , C12N15/113 , A61K38/16 , A61K38/45 , A61K45/06 , A61K31/437 , A61K31/425
摘要： The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.
-
公开(公告)号：US20140140975A1
公开(公告)日：2014-05-22
申请号：US14077610
申请日：2013-11-12
CPC分类号： A61K38/44 , A61K45/06 , C12N9/0004 , C12N9/0051 , C12Y120/04001 , A61K2300/00
摘要： The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like.
摘要翻译： 本发明一般涉及涉及谷氧还蛋白的治疗。 在一个方面，本发明的系统和方法可用于治疗具有氧化应激状况例如气道炎症或哮喘的受试者。 在一些实施方案中，可以使用谷氧还蛋白来治疗受试者。 在本发明的某些方面也提供了用于治疗涉及谷氧还蛋白的试剂盒，用于促进这种疗法的方法等。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.026 秒)
